TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release synd ...

Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in DEL, with manageable safety, supporting further ...

Grade 3/4 TEAEs included lymphopenia, neutropenia and infections. Results from the safety run-in of the Phase 3 MajesTEC-4 study highlighted the potential of TECVAYLI to be administered as a ...